SEARCH:   Advanced

Blood, 1 February 2008, Vol. 111, No. 3, pp. 1634-1643. Prepublished online as a Blood First Edition Paper on November 19, 2007; DOI 10.1182/blood-2007-04-081125. This Article Abstract Full Text (PDF) Supplemental Figures All Versions of this Article: blood-2007-04-081125v1 111/3/1634    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by van Wageningen, S. Articles by Jansen, J. H. Search for Related Content PubMed PubMed Citation Articles by van Wageningen, S. Articles by Jansen, J. H. Related Collections Neoplasia Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA Gene transactivation without direct DNA binding defines a novel gain-of-function for PML-RAR Sake van Wageningen1, Marleen C. Breems-de Ridder2, Jeannet Nigten1, Gorica Nikoloski1, Claudia A. J. Erpelinck-Verschueren2, Bob Löwenberg2, Theo de Witte1, Daniel G. Tenen3, Bert A. van der Reijden1, and Joop H. Jansen1 1 Central Hematology Laboratory and Department of Hematology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; 2 Institute of Hematology, Erasmus Medical Centre Rotterdam, Rotterdam, The Netherlands; and 3 Harvard Institutes of Medicine, Harvard Medical School and Harvard Stem Cell Institute, Boston, MA    Abstract Top Abstract Introduction Methods Results Discussion Authorship References   PML-RAR is the causative oncogene in 5% to 10% of the cases of acute myeloid leukemia. At physiological concentrations of retinoic acid, PML-RAR silences RAR target genes, blocking differentiation of the cells. At high concentrations of ligand, it (re)activates the transcription of target genes, forcing terminal differentiation. The study of RAR target genes that mediate this differentiation has identified several genes that are important for proliferation and differentiation control in normal and malignant hematopoietic cells. In this paper, we show that the PML-RAR fusion protein not only interferes with the transcription of regular RAR target genes. We show that the ID1 and ID2 promoters are activated by PML-RAR but, unexpectedly, not by wild-type RAR/RXR. Our data support a model in which the PML-RAR fusion protein regulates a novel class of target genes by interaction with the Sp1 and NF-Y transcription factors, without directly binding to the DNA, defining a gain-of-function for the oncoprotein.    Introduction Top Abstract Introduction Methods Results Discussion Authorship References   Acute promyelocytic leukemia (APL) is characterized by an excess of immature promyelocytes in the bone marrow that fail to differentiate toward mature granulocytes. In approximately 98% of the cases, the retinoic acid receptor- (RAR) gene is fused to the promyelocytic leukemia (PML) gene resulting in a PML-RAR fusion protein. The PML-RAR chimeric protein contains most of the PML sequence and a large part of RAR, including its DNA- and nuclear hormone–binding domains. APL blasts can be forced to terminally differentiate using pharmacological doses of all-trans retinoic acid (ATRA). When treated with chemotherapy, APL patients can be cured in approximately 40% of the cases. The combination of ATRA with chemotherapy leads to a remarkably high cure rate of approximately 90%,1,2 and APL currently represents the best prognostic group among the different forms of leukemia. This treatment constitutes one of the first examples of successful induction of differentiation of malignant cells yielding significant clinical results. The role of PML-RAR in transformation and terminal differentiation has been studied intensively in the past decade. PML-RAR was shown to act as a dominant oncogene, interfering with the normal function of the unrearranged PML as well as the unrearranged RAR protein. Expression of the fusion protein in immature hematopoietic cells induced a maturation block at the promyelocytic stage. Inoculation of PML-RAR–transduced bone marrow cells into irradiated syngenic mice resulted in the development of retinoic acid–sensitive leukemia.3,4 Furthermore, PML-RAR transgenic mice developed a myeloproliferative syndrome that progressed to overt leukemia in 30% to 90% of the animals after 6 to 12 months, depending on the promoter that was used.5–7 PML is a ubiquitously expressed protein that localizes to nuclear substructures termed nuclear bodies. More than 50 protein partners with various biologic functions colocalize with PML.8 In APL cells, these nuclear bodies are disrupted and dispersed into numerous small microspeckles.9 PML has multiple tumor-suppressor functions and is involved in growth control, replicative senescence, and apoptosis.10 PML–/– mice are prone to develop tumors in response to various forms of stress. In addition, PML-RAR transgenic mice develop leukemia much faster in a PML–/– background.11 Retinoic acid receptors are transcription factors that activate genes in a ligand-dependent manner. RAR binds to DNA as a heterodimer with RXR proteins. In the absence of ligand, both RAR/RXR and PML-RAR bind corepressors such as N-Cor and SMRT and recruit histone deacetylases leading to gene silencing. In the presence of ligand, the corepressors are replaced by coactivators, leading to transcriptional activation. However, PML-RAR releases the corepressors at much higher concentrations of ligand compared with the unrearranged receptors. Since PML-RAR competes with unrearranged receptors for the same DNA-binding sites, the presence of the fusion protein results in dominant silencing of retinoic acid receptor target genes at physiological concentrations of ligand. At higher, supraphysiological concentrations the fusion protein can still function as a transcriptional activator releasing the corepressor complex and allowing the transcription of genes that are important for granulocytic differentiation.12–15 The release of the differentiation block by high concentrations of retinoic acid leads to terminal granulocytic differentiation of the leukemic cells and the induction of hematologic remissions in the patients. RAR target genes are not restricted to genes that contain a consensus retinoic acid receptor–binding site in their promoter. Liganded RAR is able to repress AP-1–mediated transcription.16–18 PML-RAR abnormally regulates AP-1 activity as it stimulates AP-1–dependent transcription in the presence of ligand, whereas unliganded PML-RAR inhibits AP-1–dependent transcription.19 In addition, RAR may interfere with GATA-2–dependent transcription. Liganded RAR enhances GATA-2–dependent gene transcription via direct protein-protein interaction.20 This activity is retained in the PML-RAR fusion protein.21 Furthermore, interaction of normal retinoid receptors with the transcription factor Sp1 has been shown.22,23 Together, the data support a model in which PML-RAR interferes with RAR target gene expression in a dominant fashion, and that restoration of target gene expression by high concentrations of ligand is important for the induction of differentiation. Apart from interference with the function of both parental proteins in a dominant-negative manner, a gain-of-function for PML-RAR is suggested by various observations. PML-RAR may bind to DNA as a heterodimer with RXR, but also independently from RXR as a homodimer.24 It may bind to regular retinoic acid receptor–binding sites consisting of a repeated consensus ((A/G)G(T/G)TCA) sequence, but the required spacing between the 2 half-sites is less stringent for the fusion protein. This allows the fusion protein to bind to a wider range of DNA-target sequences compared with normal receptors.25,26 The importance of PML-RAR as a transcriptional activator of differentiation-inducing genes was shown by in vitro experiments. Expression of PML-RAR in the myeloid cell line U937 (that also expresses normal retinoic acid receptors) enhanced their sensitivity to the induction of differentiation by ATRA.27 In addition, forced expression of PML-RAR, but not RAR, in an ATRA-resistant APL cell line with constitutive degradation of the chimeric protein restored ATRA sensitivity.28 Importantly, in APL patients who became resistant to differentiation induction with ATRA during therapy, additional mutations were found in the ligand-binding domain of the RAR part of the PML-RAR fusion protein, indicating an important role for the fusion protein during the retinoic acid–induced differentiation of the leukemic cells.29 Finally, experimental mouse models in which various natural and artificial RAR fusion proteins were expressed also support a model in which interference with the function of RAR and PML is important, but in addition, they suggest that the PML-RAR fusion protein exhibits gain-of function characteristics, unique to the fusion protein.7,30 So far, the mechanisms behind these observations remain largely unclear. We have previously shown that the transcription factor inhibitors ID1 and ID2 are up-regulated upon treatment with ATRA and play a role in cell cycle arrest during APL differentiation.31 In this study, we investigated the mechanism by which these genes are regulated in APL cells. We found that ID1 and ID2 are regulated by PML-RAR through a novel mechanism, which is not shared with normal RAR, defining an as-yet-unrecognized class of retinoic acid–induced genes in APL.    Methods Top Abstract Introduction Methods Results Discussion Authorship References   Cell culture NB4, U937, and U937-PR9 cells (kindly provided by Dr P. G. Pelicci and Dr F. Grignani) were cultured in RPMI 1640 medium (Gibco, Gaithersburg, MD); Hep3b cells, in IMDM (Gibco); and HEK293 cells, in DMEM + 2 mM L-glutamine. Media were supplemented with 10% FCS (Gibco). ATRA was used at a final concentration of 10–6 M (Sigma-Aldrich, St Louis, MO) and ZnSO4, at 100 µM. Cycloheximide (ICN, Costa Mesa, CA) was added 30 minutes prior to ATRA at 4 µg/mL. DNA constructs and antibodies The human ID1 promoter was obtained from J. Campisi (University of California, Berkeley). The ID2 promoter32 was cloned into the XhoI-HindIII sites of the pGL3-basic vector (Promega, Madison WI) after amplification with the following primers: sense 5'-GTACGGTACCTCGAGTTGGGCATGGTTTGCAATA-3' and antisense 5'-GTACAGATCTAAGCTTGAAGCCCGAGCCCGGC-3'. RARE3-tk-luc,33 PML-RARR,34 and PML-RARCC, PML-RAR, RAR, and RXR expression constructs25 were as described. FLAG-PML-RAR was from A. Tomita35 and was recloned into a cytomegalovirus (CMV) expression vector. ID1 promoter deletion/mutation fragments were constructed by polymerase chain reaction (PCR) and cloned into the XhoI-HindIII sides of PGL3-basic (Promega). All constructs were sequence verified. The dominant-negative NF-YA (YAm29) construct and anti–NF-YB polyclonal antiserum were from R. Mantovani (University of Milan, Milan, Italy). pGEX-Sp1 was from H. Rotheneder (University of Vienna, Vienna, Austria). Anti-Sp1 (PEP-2), anti–NF-YA (H-209), anti-RAR (C-20), and anti-ID1 (Z-8) antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-PML rabbit antibody was as described.9 Anti-FLAG (M2) antibody was from Sigma. As a control in the chromatin immunoprecipitation (ChIP) experiments, human IgG was used (Ivegam, Sanquin, The Netherlands) Northern blotting Total cellular RNA was isolated by guanidium-isothiocyanate lysis and centrifugation on a 5.7 M cesium chloride cushion. Total RNA (10 µg) was size-fractionated by 1% agarose-formaldehyde gel electrophoresis and transferred onto Hybond N+ nylon membranes (Amersham, Buckinghamshire, United Kingdom). Filters were hybridized at 65°C overnight in phosphate buffer (2N NaH2PO4, 7% sodium dodecyl sulfate [SDS], 1 mM EDTA, pH 8, and 1% BSA). DNA probes were labeled with [32P]-dATP by random primed labeling (Boehringer, Mannheim, Germany). After hybridization, filters were washed in 0.2 x SSC/0.2% SDS for 15 minutes at 65°C. Northern blots were hybridized to radiolabeled human ID1 or ID2 probes (kindly provided by Dr S. Stegman). As a control for equal loading, filters were stripped and hybridized to a 777-bp HindIII-EcoRI human GAPDH fragment. Transactivation studies Cells were transfected using calcium-phosphate precipitates with 0.25 µg pGL3-ID1 or -ID2 promoter, 0.05 µg nuclear receptor expression vector, 0.1 µg Renilla vector (pRL-CMV; Promega), and 1 µg YAm29 expression vector. The total amount of DNA was normalized to 1.4 µg for all transfections using empty vectors. Cells were harvested 16 hours after ATRA treatment using 100 µL Passive Lysis Buffer (Promega). Firefly luciferase and Renilla luciferase activities were measured on a luminometer (Lumat LB 9507; Perkin-Elmer/Applied Biosystems, Foster City, CA) using Dual-Luciferase Reporter Assay System reagents (Promega). Electrophoretic mobility shift assay Nuclear extracts were prepared as described,36 and 5 µg was incubated in a total volume of 15 µL containing 1 µg double stranded poly(dI)-poly(dC), 10 mM HEPES, 50 mM KCL, 1 mM DTT, 1 mM PMSF, 2.5 mM MgCl2, 10% (wt/vol) glycerol, 300 µg/mL BSA, and 0.5 ng of a labeled double-stranded oligonucleotide probe: ID1 5'-CCGCCCATTGGCTGCTTTTGAACGT. To show specificity of binding, nonlabeled 100-fold excess of double-stranded oligonucleotides was added to compete for binding with the labeled probe. For this, either the ID1 probe (self-competition), a sequence not containing any CCAAT box (5'-TCAGAGTTCAAGGTTCTAGTCGCTGCGGC), or a NF-Y–binding site containing oligonucleotide from the CD10 gene (5'-ATCCCGACCAATGAGCGCACGGGGCCGGGT) was used.37 DNA-Protein complexes were resolved on a 5% nondenaturing polyacrylamide gel in 0.5 x TBE buffer. GST pull-down GST fusion proteins were produced in E coli BL21 which were induced at A600 = 0.5 with 300 µM IPTG for 4 hours. Proteins were released by sonication and loaded onto glutathione-agarose (Sigma-Aldrich) by incubation at 4°C for 2 hours in lysis buffer (0.15 M NaCl, 50 mM Tris [pH 8.3], 10 mM EDTA, 0.5% NP40, and protease inhibitors). Pull-down was performed using in vitro–translated PML-RAR and PML-RARcc (reticulocyte lysate; Promega) or rHSp1 (Promega), by 2-hour incubation at 4°C. Beads were washed in lysis buffer and subsequently resuspended in SDS-loading buffer. Chromatin immunoprecipitation DNA-protein cross-linking was done for 30 minutes at room temperature by adding formaldehyde at a final concentration of 1% directly to the culture medium. Cross-linking was stopped by the addition of glycine to a final concentration of 125 mM. Cells were washed with ice-cold phosphate-buffered saline, buffer B (10 mM EDTA, 0.5 mM EGTA, 0.25% Triton X-100, 20 mM HEPES [pH 7.6]), and buffer C (1 mM EDTA, 0.5 mM EGTA, 0.15 M NaCl, 50 mM HEPES [pH 7.6]) and resuspended in incubation buffer (0.15% SDS, 1% Triton X-100, 0.15 M NaCl, 1 mM EDTA, 0.5 mM EGTA, 20 mM HEPES [pH 7.6] and protease inhibitors) at 33 x 106 cells/mL. Chromatin was sonicated using the Bioruptor (Cosmo Bio, Tokyo, Japan), at high intensity for 15 minutes with 0.5-minute intervals. Insoluble material was removed by centrifugation at 4°C for 15 minutes. Supernatant (120 µL) was incubated with 30 µL precoated protein A/G plus agarose beads 50% vol/vol (Santa Cruz Biotechnology), 0.1% BSA, 36 µL 5 x incubation buffer, protease inhibitors and 2 to 5 µg antibody (anti–NF-YA, anti-PML, anti-FLAG, or nonspecific IgG from human serum) and rocked at 4°C for 16 hours. Beads were harvested by centrifugation and washed twice with buffer 1 (0.1% SDS, 0.1% NaDOC, 1% Triton X-100, 0.15 M NaCl, 1 mM EDTA, 0.5 mM EGTA, and 20 mM HEPES [pH 7.6]), once with buffer 2 (0.1% SDS, 0.1% NaDOC, 1% Triton X-100, 0.5 M NaCl, 1 mM EDTA, 0.5 mM EGTA, and 20 mM HEPES [pH 7.6]), once with buffer 3 (0.25 M LiCL, 0.5% NaDOC, 0.5% NP-40, 1 mM EDTA, 0.5 mM EGTA, 20 mM HEPES [pH 7.6]), and twice with buffer 4 (1 mM EDTA, 0.5 mM EGTA, 20 mM HEPES [pH 7.6]). Chromatin antibody complexes were eluted by the addition of 1% SDS and 0.1 M NaHCO3 to the pellet and incubated for 20 minutes at room temperature. Cross-linking was reversed by the addition of NaCl (0.44 M final concentration) and incubation of the eluted samples for at least 4 hours at 65°C. DNA was recovered by phenol-chloroform-isoamylalcohol extraction followed by chloroform-isoamylalcohol extraction and precipitated by the addition of 0.1 volume of 1 M sodium acetate (pH 5.2), and 2.5 volumes of ethanol. Precipitated DNA was dissolved in water, and input as well as immunoprecipitated DNA were analyzed using quantitative PCR for genomic sequences from the ID1, ID2, RARβ, and p21 promoter regions.38 Quantitative PCR Quantitative PCR to measure ID1 and ID2 mRNA expression was performed with the ABI/PRISM 7700 Sequence Detection system (ABI/PE). As a reference gene, PBGD was used. The primer/probe sequences for the ID1 gene were as follows: sense 5'-GTTACTCACGCCTCAAGGAGCT, antisense 5'-GAGAATCTCCACCTTGCTCACC, and probe FAM 5'-CCCACCCTGCCCCAGAACCG; for ID2: sense 5'-GACTGCTACTCCAAGCTCAAGGA, antisense 5'-CGTGCTGCAGGATTTCCAT, and probe FAM 5'-CCCAGCATCCCCCAGAACAAGAAGG. PCRs were done in a 50-µL reaction mixture (1.25 U AmpliTaq Gold, 1 x buffer A [both ABI/PE], 250 mM dNTPs [Pharmacia], and 5 mM MgCl2) for 10 minutes at 95°C followed by 45 cycles of 15 seconds at 95°C and 1 minute at 62°C. Quantitative PCR following ChIP was done using Sybr Green PCR (ABI/PE). Primer sequences for the ID1 promoter were as follows; sense 5'-CACTGCGAGCAGGCACTAGAC and antisense 5'-AGCCACAGCTTGTCTTT; for the ID2 promoter: sense 5'-CTGTACTCTATTTACCACCCCAGCTG and antisense 5'-GGCGTGGGCTTGGTTCTT; for the RARβ promoter: sense 5'-TTGGGTCATTTGAAGGTTAGCA and antisense 5'-CACACAGAATGAAAGATTGAATTGC; for the p21 gene, sense 5'-GGCGGGGCGGTTGTAT and antisense 5'-AAGGAACTGACTTCGGCAGC.    Results Top Abstract Introduction Methods Results Discussion Authorship References   ID1 and ID2 are direct retinoic acid–responsive genes in APL cells Basic helix-loop-helix (bHLH) transcription factors and their inhibitors, ID proteins, play crucial roles in the regulation of differentiation in various cell types. We have shown that ID1 and ID2 are up-regulated in APL cells upon exposure to ATRA.31 Up-regulation of ID1 and ID2 mRNA was confirmed with qPCR (Figure 1A,B), showing clear up-regulation within 4 hours after the addition of ATRA. To investigate whether ID1 and ID2 were directly up-regulated by ATRA, cells were treated with cycloheximide prior to the addition of ATRA to inhibit protein translation. Both ID1 and ID2 mRNAs were up-regulated within 0.5 hours by ATRA, regardless of the addition of cycloheximide (Figure 1C,D). This indicates that both genes were directly up-regulated, without intermediate protein production. View larger version (30K): [in this window] [in a new window]   Figure 1. ID1 and ID2 are direct retinoic acid target genes in NB4 cells. Quantitative PCR and Northern blot analysis of NB4 cells treated with ATRA. mRNA was isolated from NB4 cells and ID1 (A) and ID2 (B) expression was determined using specific primers and probes by quantitative PCR (n = 4). Quantities were normalized based on β-actin expression. To investigate whether the induction of ID1 and ID2 was dependent on intermediate protein production, cells were treated with cycloheximide alone (4 µg/mL) or with the combination of cycloheximide and ATRA (10–6 M). Blots were hybridized using radiolabeled ID1-specific (C) and ID2-specific (D) probes. As a control for equal loading, blots were stripped and rehybridized with GAPDH-specific probes.   The ID1 upstream promoter is transactivated by PML-RAR but not by RAR/RXR To identify the regulatory DNA sequences through which the induction of ID1 by retinoic acid was mediated, we analyzed the 5' upstream promoter sequence in transactivation assays. A 963-bp fragment of the promoter, including the putative TATA box, was cloned into a luciferase reporter construct. When expressed alone, RAR, RXR, and PML were not able to transactivate the ID1 promoter both in the absence and presence of ATRA (Figure 2A). In contrast, PML-RAR transactivated the promoter more than 12-fold in an ATRA-dependent fashion. Surprisingly, the combination of RAR/RXR did not transactivate the promoter, both in the absence and presence of ATRA. To verify that RAR and RXR were expressed and functional, a control luciferase construct was used containing 3 bona fide RAREs from the RARβ promoter (RARE3-tk-luc39). This construct was strongly transactivated in the presence of ATRA through endogenous retinoic acid receptors (Figure 2B left bars). This was further enhanced when RAR and RXR were cotransfected (Figure 2B right bars). Together this shows that PML-RAR may regulate ID1 expression through the upstream 963-bp promoter, whereas RAR/RXR cannot. View larger version (24K): [in this window] [in a new window]   Figure 2. The ID1 promoter is transactivated by PML-RAR but not by RAR/RXR. (A) Hep3B cells were transfected with the 963-bp ID1 promoter-luciferase reporter construct (ID1-luc) together with a control vector expressing Renilla luciferase. In addition, vectors coding for the various proteins indicated in the figure were transfected. Transactivation is expressed as arbitrary units and is corrected for transfection efficiency measured by Renilla luciferase. Background luminescence of the cells transfected with only the reporter construct without nuclear receptors and in the absence of ATRA was set at 1. Cells were cultured for 16 hours without () and with () ATRA. Mean values and standard deviations from 3 independent experiments (± SD) are shown. (B) To show transactivation by unrearranged retinoic acid receptors, cells were transfected with the RARE3-tk-luc vector, containing 3 bona fide RAREs. Mean values of 3 independent experiments (± SD) are shown. (C) ID1 expression is increased by PML-RAR in the presence of ATRA. The zinc-inducible PML-RAR cell line U937-PR9 was grown in the absence (left panel) or presence (right panel) of zinc for 16 hours. Cells were treated with ATRA and harvested at the indicated time points. Proteins were size-fractionated by SDS–polyacrylamide gel electrophoresis (SDS-PAGE). Immunostaining was done with anti-ID1 antibody.   To test whether PML-RAR expression would result in ATRA-dependent induction of the endogenous ID1 gene, we used the U937-PR9 cell line that is stably transfected with a Zn2+-inducible PML-RAR expression cassette.34 In PML-RAR–expressing U937 cells, ATRA strongly induced ID1 expression (Figure 2C right panel), in contrast to U937 cells that did not express PML-RAR (Figure 2C left panel). Transactivation of the ID1 promoter is dependent on GC and CCAAT box motifs To determine the DNA sequences that are relevant for the observed PML-RAR–dependent transactivation, we analyzed the 963-bp upstream promoter construct of the ID1 gene further. The consensus RAR/RXR-binding sequence (RARE) consists of a repeated (A/G)G(T/G)TCA sequence that is separated by 2 or 5 base pairs. However, in the 963-bp ID1 promoter, no consensus RARE was found. As PML-RAR may bind to a much wider variety of DNA sequences,25,26 we made luciferase constructs with different promoter truncations. All the truncation mutants could still be transactivated by PML-RAR (Figure 3B), including the smallest, 121-bp promoter construct. This construct does not contain any sequence that even remotely resembles a retinoic acid receptor–binding site (Figure 3A). Analysis of the 121-bp promoter sequence for putative binding sites for other transcription factors showed a perfect consensus-binding site for the transcription factors NF-Y (CCAAT box) and Sp1 (GC box). To test their relevance, we mutated these sites individually and in combination in the context of the 963-bp promoter fragment. Mutation of the GC box or the CCAAT box alone partially impaired transactivation by PML-RAR, while deletion of the GC box and the CCAAT box in combination almost completely abolished transactivation (Figure 3C; raw Renilla and Firefly luciferase data are given in Figure S1, available on the Blood website; see the Supplemental Materials link at the top of the online article). This indicated that transactivation of the ID1 promoter by PML-RAR was dependent on the GC and CCAAT motifs. View larger version (30K): [in this window] [in a new window]   Figure 3. The CCAAT and GC box in the ID1 promoter are required for PML-RAR–mediated transactivation. (A) ID1 promoter region showing the presence of consensus Sp1- and NF-Y–binding sites. (B) Transactivation of ID1 promoter-luciferase constructs. Several deletion constructs were generated and transfected in combination with RAR plus RXR, or with PML-RAR. Transactivation assays were performed as described in Figure 2. Mean values from 3 independent experiments (± SD) are shown. (C) To investigate the importance of the putative Sp1- and NF-Y–binding sites in the – 121-bp upstream promoter sequence of the ID1 gene for transactivation by PML-RAR, these sites were mutated in the context of the – 963-bp promoter fragment. Mutations were introduced either alone, or in combination. Transactivation by PML-RAR was performed as described in Figure 1. Sequences were mutated as follows: GC box: CCGCCC was replaced by CTATCC; NF-Y site: ATTGG was replaced by ACACG. Transactivation was significantly lower in the promoter fragments with one mutated binding site in comparison with the wt promoter fragment (P < .01).   Functional NF-Y is necessary for transactivation of the ID1 promoter by PML-RAR Sp1 and NF-Y are ubiquitously expressed transcription factors. NF-Y is a trimeric protein complex consisting of the subunits NF-YA, NF-YB, and NF-YC. All 3 subunits are necessary for the complex to bind to the DNA.40 Using real-time PCR, we confirmed that Sp1 and all 3 NF-Y subunits were expressed in primary APL cells (Figure S2). Binding of Sp1 to the promoter of ID1 was shown previously.41 Therefore, we tested whether NF-Y was able to bind to the CCAAT site from the ID1 promoter. Incubation of a radioactively labeled DNA probe containing the CCAAT box with cellular protein extracts resulted in a clear shifted complex (Figure 4A lane 1). This shift was competed by a 100-fold excess of nonlabeled probe (Figure 4A lane 2) and by an excess of an oligo containing the NF-Y–binding site of the CD10 promoter (Figure 4 lane 542), but not by an excess of probe lacking a NF-Y–binding site (Figure 4A lane 3). When anti–NF-YB antiserum was added (Figure 4A lane 4) the protein-DNA complex was supershifted, identifying the DNA-binding protein complex as NF-Y. To further test whether NF-Y is present on the endogenous ID1 promoter, we performed chromatin immunoprecipitation (ChIP) assays. Using anti–NF-YA antibody, recovery of the ID1 promoter sequences from U937 cells was more than 70 times higher than recovery with nonspecific IgGs (Figure 4B right bars). In the same experiment, no enrichment was seen for the RARβ promoter (Figure 4B left bars), indicating that NF-Y is present on the endogenous ID1 promoter but not on the RARβ promoter. View larger version (29K): [in this window] [in a new window]   Figure 4. NF-Y binds to the CCAAT box element from the ID1 promoter and is required for PML-RAR–mediated transactivation. (A) EMSA showing binding of NF-Y to the putative NF-Y–binding site from the ID1 promoter. Hep3B nuclear extracts were incubated with a labeled DNA probe containing the NF-Y box from the ID1 promoter region. A clearly shifted protein-DNA complex was seen (lane 1). Competition experiments were done with 100 x cold ID1 probe (lane 2) and with an unlabeled probe containing the confirmed NF-Y–binding site from the CD10 gene promoter (lane 5). In addition, a sequence without any recognizable NF-Y–binding site was used for competition (lane 3). Addition of anti–NF-YB antibody shifted the complex to a higher molecular weight complex (lane 4). Arrows indicate free probe (1), shifted DNA-protein complex (2), and the supershifted DNA-protein-antibody complex (3). (B) To detect DNA-binding of NF-Y in intact cells, ChIP assays were performed using anti–NF-YA antibodies. As a control, the nonspecific IgG fraction from human serum was used. The y-axis shows the recovery (%) of ID1 or RARβ sequences relative to the input. In U937 cells, NF-Y clearly bound to the ID1 promoter (right bars), but not to the RARβ gene (left bars). Mean values from 3 independent experiments plus or minus SD are shown. (C) To further show the importance of NF-Y for the PML-RAR–mediated transcriptional activation of ID1, transfections (as described in Figure 2) were performed using the dominant-negative NF-YA subunit (Yam29) and the 963 ID1 promoter construct. In the presence of YAm29, PML-RAR–mediated transcription was severely diminished (right bars). (D) To investigate the importance of different domains of PML-RAR, vectors encoding the DNA-binding–defective PML-RARR mutant, and a mutant lacking the coiled-coil protein-protein interaction domain of PML (PML-RARCC), were used. In addition, a PLZF-RAR expression construct was used. Transfections were performed as in Figure 2 using the 963 ID1 promoter construct; mean values of 3 independent experiments plus or minus SD are shown.   A dominant-negative form of NF-YA has been described (YAm29).43 This mutated NF-YA subunit can still bind to the NF-YB and NF-YC subunits, but is not able to bind to DNA, preventing the formation of a functional trimeric NF-Y complex. To investigate whether functional NF-Y was necessary for the transactivation of ID1, the YAm29 mutant was tested in a transactivation assay. Transactivation of ID1 by PML-RAR upon ATRA treatment was severely decreased in the presence of dominant-negative NF-YA (Figure 4C). This effect was promoter specific as YAm29 did not influence transactivation of the RARβ promoter construct (RARE3-tk-luc) by PML-RAR or RAR/RXR (data not shown). Up-regulation of ID1 is dependent on PML-RAR but does not require the DNA-binding domain of the fusion protein To test whether PML-RAR might transactivate the ID1 promoter without directly binding to the DNA, we used a PML-RAR construct from which the DNA-binding domain was deleted (PML-RAR/R,34). PML-RAR/R has been shown to be unable to transactivate a promoter containing a bona fide RARE. In contrast, PML-RAR/R retained the ability to transactivate the ID1 promoter (Figure 4D). Similar results were found when the transactivation assay was repeated in the myeloid cell line HL-60 (Figure S3). This indicated that transactivation of the ID1 promoter by PML-RAR does not require direct binding of PML-RAR to the DNA. PLZF-RAR is generated by a t(11;17) translocation that is found in approximately 2% of the patients with APL. It contains the same part of the retinoic acid receptor as PML-RAR. Similar to PML-RAR, this fusion protein may form homodimers with DNA-binding capacity.44 Interestingly, PLZF-RAR was not able to transactivate the ID1 promoter, suggesting that the PML part of PML-RAR is necessary for transactivation of the ID1 promoter (Figure 4D). When the coiled-coil domain of PML-RAR was deleted (PML-RAR/CC25,34), it was no longer able to transactivate the ID1 promoter (Figure 4D). As this domain is involved in protein-protein interactions, this suggested that PML-RAR homodimerization or interaction of PML-RAR with another protein was necessary for the transactivation of ID1. The ID2 promoter is also transactivated by PML-RAR but not by RAR/RXR To investigate whether ID2 was regulated in a similar manner as ID1, we cloned the upstream promoter of ID2 (812 bp) into a luciferase reporter plasmid. Similar to ID1, no consensus retinoic acid receptor–binding site could be found in the ID2 promoter sequence. Also comparable with ID1, RAR, RXR, PML, PLZF-RAR, and RAR/RXR did not transactivate the ID2 promoter, whereas PML-RAR did (Figure 5A). Furthermore, transactivation of ID2 by PML-RAR was abolished in the presence of dominant-negative NF-YA (Figure 5B). Inspection of the ID2 promoter sequence revealed 3 NF-Y and 5 Sp1 consensus-binding sites (Figure 5C). Together, these data show that like ID1, ID2 may also be transactivated by PML-RAR without direct DNA binding of the fusion protein. View larger version (32K): [in this window] [in a new window]   Figure 5. The ID2 promoter is transactivated by PML-RAR but not by RAR/RXR. (A) Cells were transiently transfected with a 812-bp ID2-luciferase reporter construct (ID2-luc). Transfections and controls were as described in Figure 2. Background luminescence of the cells transfected with only a reporter construct (no nuclear receptor and no ATRA) was set at 1. Transactivation was measured after treatment without () and with () 10–6 M ATRA. Mean values from at least 3 independent experiments plus or minus SD are shown. (B) Dominant-negative NF-Y (Yam29) inhibits the transactivation of the ID2 promoter construct by PML-RAR. Transfections were done as described in Figure 2; mean values of 3 independent experiments plus or minus SD are shown. (C) Promoter region of the ID2 gene with putative Sp1- and NF-Y–binding sites.   PML-RAR directly interacts with Sp1 NF-Y and Sp1 have been shown to work in concert on many promoters. Direct physical interaction between Sp1 and NF-YA has been shown, indicating that these proteins may bind to adjacent DNA-binding sites and form a complex that regulates transcription.45 We investigated whether PML-RAR could physically interact with Sp1 or NF-YA. GST-tagged, bacterially produced NF-YA and Sp1 proteins were made, as well as in vitro–translated (reticulocyte lysate) PML-RAR for GST pull-down experiments. rhSp1 was commercially available. Whereas a clear interaction was observed between GST-NF-YA and recombinant Sp1 (Figure 6A), in none of the conditions tested could we show a direct interaction between NF-YA and PML-RAR. In contrast, an interaction between PML-RAR and Sp1 was readily observed, whereas no interaction was seen with nonloaded or GST-loaded beads (Figure 6A). GST-Sp1 was also able to capture PML-RAR/CC, although with a much lower efficiency than PML-RAR. This suggests that the binding of PML-RAR is partly through the coiled-coil region and partly through the RAR part of the fusion protein. This is in agreement with earlier publications that have shown binding of both PML and RAR to Sp1.22,46 View larger version (22K): [in this window] [in a new window]   Figure 6. PML-RAR binds Sp1 and binds to the endogenous ID1 promoter. (A) To test binding of PML-RAR to Sp1 and NF-Y, GST pull-down experiments were performed. Empty beads and beads loaded with GST or GST-NF-YA (left panels) were incubated with in vitro–translated Sp1 (positive control) or in vitro–translated PML-RAR. GST-Sp1 (right panels) was incubated with in vitro–translated PML-RAR or PML-RARCC. Beads were washed and subsequently resuspended in loading buffer. Protein was resolved on SDS-PAGE. Immunostaining was performed with anti-Sp1 or anti-RAR antibody. Clear interactions between NF-YA and Sp1 and between PML-RAR and Sp1 were observed. To show binding of PML-RAR to the endogenous RARβ (B) and ID1 (C) genes, ChIP assays were performed in PML-RAR–positive NB4 cells and in PML-RAR–negative U937 cells. Cells were treated with ATRA for 30 minutes. ChIP was done with anti-PML antiserum. As a control, the nonspecific IgG fraction from human serum was used. The Y-axis shows the recovery (%) of ID1 or RARβ sequences relative to the input. Mean values plus or minus SD of 4 independent experiments are shown.   PML and PML-RAR are present on the endogenous ID1 promoter To show the physical interaction of PML-RAR with the endogenous ID1 and ID2 promoters in intact cells, we performed ChIP assays using PML-specific antibodies. The RARβ promoter, which contains a well-defined RARE, served as a positive control. In NB4 cells, we found a clear enrichment for the RARβ promoter (Figure 6B right panel). In contrast, in U937 cells that are PML-RAR negative, no enrichment for the RARβ promoter was seen (Figure 6B left panel), indicating that PML-RAR binds to the RARβ promoter in NB4 cells. The ID1 gene was also precipitated with anti-PML antibody in NB4 cells (Figure 6C right panel). However, this was observed not only in the PML-RAR–positive NB4 cells, but also in the PML-RAR–negative U937 cells (Figure 6C left panel). This indicates that in U937 cells, unrearranged PML protein was present on the ID1 promoter. As the anti-PML does not discriminate between PML and PML-RAR, we could not determine which of these 2 proteins was bound to the ID1 promoter in NB4 cells. To investigate this further, we used a FLAG-tagged PML-RAR expression construct, allowing us to unequivocally identify binding by the PML-RAR fusion protein. HEK-293 cells were transfected with FLAG-PML-RAR (Figure 7A). As a negative control, ChIP was performed using nonspecific IgGs. We compared the presence of (FLAG-tagged) PML-RAR and NF-Y on the 2 classical ATRA target genes RARβ and p21, and on ID1 and ID2. Enrichment of all 4 promoters was found using anti-FLAG antibody, indicating that PML-RAR was bound to these 4 genes in intact cells (Figure 7A, compare top and middle rows). Using anti–NF-Y antibody, enrichment of the ID1 and ID2 promoters was found but no enrichment of RARβ and p21, indicating that NF-Y was present on ID1 and ID2, but not on the 2 classical ATRA target genes RARβ and p21. To determine whether the presence of PML-RAR and NF-Y on the different promoters would be altered by the presence of retinoic acid, ChIP assays were performed in the presence and the absence of ATRA (Figure 7A middle and bottom rows). ATRA did not influence the binding of NF-Y or PML-RAR to these promoters, showing that their binding is ligand independent. View larger version (21K): [in this window] [in a new window]   Figure 7. Binding of PML-RAR to the endogenous p21, RAR-β, ID1, and ID2 genes. (A) To show binding of PML-RAR and NF-Y to the endogenous p21, RAR-β, ID1, and ID2 genes, ChIP assays were performed. As anti-PML antibodies do not discriminate between the unrearranged PML protein and the PML-RAR fusion protein, FLAG-tagged PML-RAR was used. Cells were transfected with or without FLAG-PML-RAR and cultured in the presence or absence of 10–6 M ATRA. ChIP was performed using anti-FLAG antibodies, anti–NF-YA antibodies, and control IgGs. The Y-axis shows the recovery (%) of ID1/ID2/p21 or RARβ sequences relative to the input. Mean values of 3 independent experiments (± SD) are shown. (B) Dominant-negative and gain-of-function model for PML-RAR. Genes that are regulated through a retinoic acid–responsive element (RARE) may be bound by PML-RAR (1). Competition with normal, unrearranged retinoid receptors results in a dominant-negative silencing of the gene by PML-RAR in the absence of ligand. Addition of high-dose retinoic acid may reverse the silencing, allowing transcription. Sp1- and NF-Y–regulated genes may be targeted by PML-RAR through interaction with Sp1 (2). Tethering of PML-RAR to these promoters renders them responsive to retinoic acid, representing a gain-of-function for the PML-RAR fusion protein.   Together, these data show that there are 2 different mechanisms by which PML-RAR may regulate the transcription of target genes (Figure 7B). The first class of target genes consists of genes that contain a retinoic acid response element in their promoter. These genes are normally regulated by unrearranged retinoic acid receptors and may be deregulated by PML-RAR in a dominant-negative manner in the absence of ligand. In the presence of high concentrations of ligand, their expression is restored. The second class of target genes consists of genes that are not normally regulated by retinoic acid receptors. Fusion of the RAR moiety to PML renders these genes responsive to retinoic acid, which defines a novel gain of function for the PML-RAR fusion protein.    Discussion Top Abstract Introduction Methods Results Discussion Authorship References   The successful treatment of APL with high-dose retinoic acid has shown that the differentiation block of the malignant cells can be overcome, leading to terminal differentiation of the leukemic cells and disappearance of the disease. As this is one of the first examples of successful differentiation-induction therapy in cancer, many studies focused on the molecular mechanisms that contribute to the transformation to leukemia, and on the mechanisms that mediate the retinoic acid–induced differentiation of the cells. PML-RAR was shown to interfere with the expression of normal RAR target genes. RAR is an important modulator of granulopoiesis and acts either by direct binding to the DNA, or through interaction with other transcription factors. In this report, we show that PML-RAR interacts with Sp1 and may interfere with the expression of genes that are not normally regulated by retinoic acid receptors. Previously, it was shown that both unrearranged PML46 and unrearranged RAR/RXR complexes22,23 are able to interact with Sp1. Therefore, the interaction of PML-RAR with Sp1 could be mediated by the RAR part as well as the PML part of the fusion protein. Here we show that PML-RAR binds Sp1 and that this binding is significantly less efficient when the coiled-coil domain is deleted. The lack of response of the ID1 and the ID2 promoters to RAR/RXR, PLZF-RAR, and PML-RAR/CC (Figures 2, 5) suggests that the PML part of the fusion protein is essential for regulating transcription. We show that PML-RAR physically interacts with Sp1 in the absence of DNA (Figure 6). Roder et al have shown that NF-Y and Sp1 interact physically in the absence of DNA,45 and we obtained the same result (Figure 6). This suggests that the PML-RAR/Sp1/NF-Y complex may form before binding to DNA. Figure 3C suggests that the PML-RAR/Sp1/NF-Y complex still binds, although less efficiently, to the ID1 promoter when one transcription factor–binding site is mutated. Figure 4C shows that the presence of a dominant-negative form of NF-Y abolishes transactivation of the ID1 promoter by PML-RAR. We hypothesize that this dominant-negative form of NF-Y disrupts the PML-RAR/Sp1/NF-Y complex and thereby impairs binding to and transactivation of the ID1 promoter. We propose a model in which PML-RAR binds to a DNA-bound Sp1-NF-Y complex, rendering the expression of these genes sensitive to ATRA, and defining a novel gain-of-function for the fusion protein (Figure 7B). In the ChIP experiments, we show that unrearranged PML is recruited to the ID1 gene (Figure 6C). The physiological meaning of this remains unclear as no effect of PML was observed in the transactivation assays. As Sp1 is involved in the transcriptional control of various myeloid-specific genes,47,48 deregulation of its target genes may be relevant in APL. For ID1 and ID2, a role in myelopoiesis and in APL was described previously. Overexpression of ID1 or ID2 in NB4 cells inhibits their proliferation and induces a G0/G1 arrest.31 In addition, ectopic expression of ID1 in CD34+ cells inhibited eosinophil development, whereas neutrophilic differentiation was enhanced. Expression of ID2 accelerated the definitive maturation of myeloid cells.49 Other genes may be targeted by a similar mechanism as well. The promoter of the important retinoic acid–responsive gene C/EBPβ was transactivated by PML-RAR, but also lacks a consensus RARE within the tested region.50,51 Possibly, also this gene is (de)regulated by tethering of PML-RAR to the promoter through protein-protein interactions rather than by direct DNA binding. Apart from the DNA-binding domain from RAR, the coiled-coil domain of PML was shown to be important for optimal induction of terminal differentiation by the fusion protein.52 This suggested that homodimerization of PML-RAR is an important feature of the fusion protein, but might also indicate that other protein-protein interactions mediated through the PML part are involved. Several alternative RAR fusion proteins occur at low frequency (2% of the cases) in APL patients, in which the same part of RAR is fused to other proteins than PML (reviewed in Zelent et al44). Common to the various RAR partner proteins is the presence of a dimerization domain, suggesting that homodimerization is an important property of these fusion proteins. However, depending on the fusion partner, the sensitivity to retinoic acid differs, suggesting a broader role for the RAR partner protein than just the provision of a dimerization domain. Specifically, PLZF-RAR–positive leukemia appears to be more resistant to ATRA, which has been explained by the recruitment of corepressors by the PLZF part of the fusion protein that are not released upon treatment with ATRA.15,53 This insensitivity could be reversed, as treatment with a combination of ATRA and granulocyte colony-stimulating factor (G-CSF) induced granulocytic differentiation in a synergistic manner.54 In addition, in transgenic mice, different types of disease with different sensitivities to ATRA developed for the various fusion proteins.7,30 Furthermore, when RAR fusion proteins were made by the coupling of RAR to artificial dimerization domains, several characteristics of PML-RAR were recapitulated in vitro, but in vivo these proteins induced leukemia with very low efficiency.55 Interestingly, when these fusion proteins were expressed in a PML–/– background, the animals still did not develop leukemia efficiently, leading to the conclusion that the mere combination of disruption of PML and dimerization of RAR does not recapitulate the full oncogenic potential of PML-RAR, and that the fusion protein has gain-of-function characteristics. Together, this showed that dimerization of RAR is important but not sufficient to reproduce the complete phenotype of PML-RAR. It remains to be investigated whether PML-RAR recruits corepressors to the promoters of Sp1 and NF-Y target genes. This would lead to repression of gene expression in the absence of ATRA, possibly contributing to transformation of the cells, similar to the effect of PML-RAR on regular retinoic acid receptor target genes. So far, we did not observe important down-regulation of ID1 and ID2 mRNA in freshly isolated leukemia cells from APL patient cells compared with non-APL acute myeloid leukemia cells, suggesting that this is not the case (data not shown). However, as ID1 and ID2 expression in most leukemic samples was low, further studies are required. Potentially, RXR may also be present in the PML-RAR/Sp1/NF-Y complex. RXR is an essential part of the PML-RAR complex during transformation, and synergy has been shown between ATRA- and RXR-specific agonist on transcriptional activation.24–26,56 Therefore, RXR-specific agonist may also affect transcription of Sp1 and NF-Y target genes. In summary, we define a novel, Sp1- and NF-Y–dependent mechanism by which the PML-RAR fusion protein interferes with gene transcription. This implicates that PML-RAR (de)regulates an additional class of genes that is normally not regulated by retinoid receptors and defines a gain-of-function for the PML-RAR fusion protein.    Authorship Top Abstract Introduction Methods Results Discussion Authorship References   Contribution: S.W. designed and performed research, analyzed data, and wrote the paper; M.C.B.-R. designed and performed research, and analyzed data; J.N., G.N., and C.A.J.E.-V. performed research and analyzed data; B.L., T.W., and B.A.R. designed research; D.G.T. analyzed data; J.H.J. designed research, analyzed data, and wrote the paper. Conflict-of-interest disclosure: The authors declare no competing financial interests. Correspondence: J. H. Jansen, Central Hematology Laboratory and Dept of Hematology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Geert Grooteplein zuid 8, PO Box 9101, 6500 HB Nijmegen, The Netherlands; e-mail: j.jansen{at}chl.umcn.nl.    Acknowledgments   We thank Dr P. G. Pelicci (European Institute of Oncology, Milan, Italy), Dr F. Grignani (Perugia University, Perugia, Italy), Dr J. Campisi (University of California, Berkeley), Dr A. Tomita (Nagoya University, Nagoya, Japan), Dr H. Rotheneder (University of Vienna, Vienna, Austria), and Dr R. Mantovani (University of Milan, Milan, Italy) for supplying materials. We thank W.-J. Welboren and Dr M. L. Lohrum for advice on the ChIP protocol. This work was supported by the Dutch Cancer Society (grant no. 03-2897).    Footnotes   Submitted April 2, 2007; accepted November 8, 2007. Prepublished online as Blood First Edition Paper, November 19, 2007 DOI: 10.1182/blood-2007-04-081125 S.W. and M.C.B.-R. contributed equally to this work. The online version of this article contains a data supplement. The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.    References Top Abstract Introduction Methods Results Discussion Authorship References   Mistry AR, Pedersen EW, Solomon E, Grimwade D. The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease. Blood Rev 2003; 17:71–97.[CrossRef][Medline] [Order article via Infotrieve] Sanz MA, Martin G, Gonzalez M, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 2004; 103:1237–1243.[Abstract/Free Full Text] Minucci S, Monestiroli S, Giavara S, et al. PML-RAR induces promyelocytic leukemias with high efficiency following retroviral gene transfer into purified murine hematopoietic progenitors. Blood 2002; 100:2989–2995.[Abstract/Free Full Text] Grignani F, Valtieri M, Gabbianelli M, et al. PML/RAR alpha fusion protein expression in normal human hematopoietic progenitors dictates myeloid commitment and the promyelocytic phenotype. Blood 2000; 96:1531–1537.[Abstract/Free Full Text] Westervelt P, Lane AA, Pollock JL, et al. High-penetrance mouse model of acute promyelocytic leukemia with very low levels of PML-RARalpha expression. Blood 2003; 102:1857–1865.[Abstract/Free Full Text] Pollock JL, Westervelt P, Walter MJ, Lane AA, Ley TJ. Mouse models of acute promyelocytic leukemia. Curr Opin Hematol 2001; 8:206–211.[CrossRef][Medline] [Order article via Infotrieve] Pandolfi PP. In vivo analysis of the molecular genetics of acute promyelocytic leukemia. Oncogene 2001; 20:5726–5735.[CrossRef][Medline] [Order article via Infotrieve] Borden KL. Pondering the promyelocytic leukemia protein (PML) puzzle: possible functions for PML nuclear bodies. Mol Cell Biol 2002; 22:5259–5269.[Free Full Text] Weis K, Rambaud S, Lavau C, et al. Retinoic acid regulates aberrant nuclear localization of PML-RAR alpha in acute promyelocytic leukemia cells. Cell 1994; 76:345–356.[CrossRef][Medline] [Order article via Infotrieve] Salomoni P and Pandolfi PP. The role of PML in tumor suppression. Cell 2002; 108:165–170.[CrossRef][Medline] [Order article via Infotrieve] Rego EM and Pandolfi PP. Analysis of the molecular genetics of acute promyelocytic leukemia in mouse models. Semin Hematol 2001; 38:54–70.[CrossRef][Medline] [Order article via Infotrieve] Minucci S, Maccarana M, Cioce M, et al. Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. Mol Cell 2000; 5:811–820.[CrossRef][Medline] [Order article via Infotrieve] Lin RJ, Nagy L, Inoue S, Shao W, Miller WH JR, Evans RM. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 1998; 391:811–814.[CrossRef][Medline] [Order article via Infotrieve] He LZ, Guidez F, Tribioli C, et al. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat Genet 1998; 18:126–135.[CrossRef][Medline] [Order article via Infotrieve] Grignani F, De Matteis S, Nervi C, et al. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 1998; 391:815–818.[CrossRef][Medline] [Order article via Infotrieve] Yang-Yen HF, Zhang XK, Graupner G, et al. Antagonism between retinoic acid receptors and AP-1: implications for tumor promotion and inflammation. New Biol 1991; 3:1206–1219.[Medline] [Order article via Infotrieve] Schule R, Rangarajan P, Yang N, et al. Retinoic acid is a negative regulator of AP-1-responsive genes. Proc Natl Acad Sci U S A 1991; 88:6092–6096.[Abstract/Free Full Text] Nicholson RC, Mader S, Nagpal S, Leid M, Rochette-Egly C, Chambon P. Negative regulation of the rat stromelysin gene promoter by retinoic acid is mediated by an AP1 binding site. EMBO J 1990; 9:4443–4454.[Medline] [Order article via Infotrieve] Doucas V, Brockes JP, Yaniv M, de The H, Dejean A. The PML-retinoic acid receptor alpha translocation converts the receptor from an inhibitor to a retinoic acid-dependent activator of transcription factor AP-1. Proc Natl Acad Sci U S A 1993; 90:9345–9349.[Abstract/Free Full Text] Tsuzuki S, Towatari M, Saito H, Enver T. Potentiation of GATA-2 activity through interactions with the promyelocytic leukemia protein (PML) and the t(15;17)-generated PML-retinoic acid receptor alpha oncoprotein. Mol Cell Biol 2000; 20:6276–6286.[Abstract/Free Full Text] Tsuzuki S, Kitajima K, Nakano T, Glasow A, Zelent A, Enver T. Cross talk between retinoic acid signaling and transcription factor GATA-2. Mol Cell Biol 2004; 24:6824–6836.[Abstract/Free Full Text] Suzuki Y, Shimada J, Shudo K, Matsumura M, Crippa MP, Kojima S. Physical interaction between retinoic acid receptor and Sp1: mechanism for induction of urokinase by retinoic acid. Blood 1999; 93:4264–4276.[Abstract/Free Full Text] Shimada J, Suzuki Y, Kim SJ, Wang PC, Matsumura M, Kojima S. Transactivation via RAR/RXR-Sp1 interaction: characterization of binding between Sp1 and GC box motif. Mol Endocrinol 2001; 15:1677–1692.[Abstract/Free Full Text] Perez A, Kastner P, Sethi S, Lutz Y, Reibel C, Chambon P. PMLRAR homodimers: distinct DNA binding properties and heteromeric interactions with RXR. EMBO J 1993; 12:3171–3182.[Medline] [Order article via Infotrieve] Jansen JH, Mahfoudi A, Rambaud S, Lavau C, Wahli W, Dejean A. Multimeric complexes of the PML-retinoic acid receptor alpha fusion protein in acute promyelocytic leukemia cells and interference with retinoid and peroxisome-proliferator signaling pathways. Proc Natl Acad Sci U S A 1995; 92:7401–7405.[Abstract/Free Full Text] Kamashev D, Vitoux D, De The H. PML-RARA-RXR oligomers mediate retinoid and rexinoid/cAMP cross-talk in acute promyelocytic leukemia cell differentiation. J Exp Med 2004; 199:1163–1174.[Abstract/Free Full Text] Grignani F, Ferrucci PF, Testa U, et al. The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell 1993; 74:423–431.[CrossRef][Medline] [Order article via Infotrieve] Fanelli M, Minucci S, Gelmetti V, Nervi C, Gambacorti-Passerini C, Pelicci PG. Constitutive degradation of PML/RARalpha through the proteasome pathway mediates retinoic acid resistance. Blood 1999; 93:1477–1481.[Abstract/Free Full Text] Imaizumi M, Suzuki H, Yoshinari M, et al. Mutations in the E-domain of RAR portion of the PML/RAR chimeric gene may confer clinical resistance to all-trans retinoic acid in acute promyelocytic leukemia. Blood 1998; 92:374–382.[Abstract/Free Full Text] Matsushita H, Scaglioni PP, Bhaumik M, et al. In vivo analysis of the role of aberrant histone deacetylase recruitment and RAR alpha blockade in the pathogenesis of acute promyelocytic leukemia. J Exp Med 2006; 203:821–828.[Abstract/Free Full Text] Nigten J, Breems-de Ridder MC, Erpelinck-Verschueren CA, et al. ID1 and ID2 are retinoic acid responsive genes and induce a G0/G1 accumulation in acute promyelocytic leukemia cells. Leukemia 2005; 19:799–805.[CrossRef][Medline] [Order article via Infotrieve] Kurabayashi M, Jeyaseelan R, Kedes L. Doxorubicin represses the function of the myogenic helix-loop-helix transcription factor MyoD: involvement of Id gene induction. J Biol Chem 1994; 269:6031–6039.[Abstract/Free Full Text] de The H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 1991; 66:675–684.[CrossRef][Medline] [Order article via Infotrieve] Grignani F, Testa U, Rogaia D, et al. Effects on differentiation by the promyelocytic leukemia PML/RARalpha protein depend on the fusion of the PML protein dimerization and RARalpha DNA binding domains. EMBO J 1996; 15:4949–4958.[Medline] [Order article via Infotrieve] Tomita A, Buchholz DR, Obata K, Shi YB. Fusion protein of retinoic acid receptor alpha with promyelocytic leukemia protein or promyelocytic leukemia zinc finger protein recruits N-CoR-TBLR1 corepressor complex to repress transcription in vivo. J Biol Chem 2003; 278:30788–30795.[Abstract/Free Full Text] Andrews NC and Faller DV. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res 1991; 19:2499.[Free Full Text] Inoue T, Kamiyama J, Sakai T. Sp1 and NF-Y synergistically mediate the effect of vitamin D(3) in the p27(Kip1) gene promoter that lacks vitamin D response elements. J Biol Chem 1999; 274:32309–32317.[Abstract/Free Full Text] Rietveld LE, Caldenhoven E, Stunnenberg HG. In vivo repression of an erythroid-specific gene by distinct corepressor complexes. EMBO J 2002; 21:1389–1397.[CrossRef][Medline] [Order article via Infotrieve] de The H, Vivanco-Ruiz MM, Tiollais P, Stunnenberg H, Dejean A. Identification of a retinoic acid responsive element in the retinoic acid receptor beta gene. Nature 1990; 343:177–180.[CrossRef][Medline] [Order article via Infotrieve] Mantovani R. The molecular biology of the CCAAT-binding factor NF-Y. Gene 1999; 239:15–27.[CrossRef][Medline] [Order article via Infotrieve] Singh J, Murata K, Itahana Y, Desprez PY. Constitutive expression of the Id-1 promoter in human metastatic breast cancer cells is linked with the loss of NF-1/Rb/HDAC-1 transcription repressor complex. Oncogene 2002; 21:1812–1822.[CrossRef][Medline] [Order article via Infotrieve] Ishimaru F, Mari B, Shipp MA. The type 2 CD10/neutral endopeptidase 24.11 promoter: functional characterization and tissue-specific regulation by CBF/NF-Y isoforms. Blood 1997; 89:4136–4145.[Abstract/Free Full Text] Mantovani R, Li XY, Pessara U, Hooft van Huisjduijnen R, Benoist C, Mathis D. Dominant negative analogs of NF-YA. J Biol Chem 1994; 269:20340–20346.[Abstract/Free Full Text] Zelent A, Guidez F, Melnick A, Waxman S, Licht JD. Translocations of the RARalpha gene in acute promyelocytic leukemia. Oncogene 2001; 20:7186–7203.[CrossRef][Medline] [Order article via Infotrieve] Roder K, Wolf SS, Larkin KJ, Schweizer M. Interaction between the two ubiquitously expressed transcription factors NF-Y and Sp1. Gene 1999; 234:61–69.[CrossRef][Medline] [Order article via Infotrieve] Vallian S, Chin KV, Chang KS. The promyelocytic leukemia protein interacts with Sp1 and inhibits its transactivation of the epidermal growth factor receptor promoter. Mol Cell Biol 1998; 18:7147–7156.[Abstract/Free Full Text] Resendes KK and Rosmarin AG. Sp1 control of gene expression in myeloid cells. Crit Rev Eukaryot Gene Expr 2004; 14:171–181.[CrossRef][Medline] [Order article via Infotrieve] Friedman AD. Transcriptional regulation of granulocyte and monocyte development. Oncogene 2002; 21:3377–3390.[CrossRef][Medline] [Order article via Infotrieve] Buitenhuis M, van Deutekom HW, Verhagen LP, et al. Differential regulation of granulopoiesis by the basic helix-loop-helix transcriptional inhibitors Id1 and Id2. Blood 2005; 105:4272–4281.[Abstract/Free Full Text] Hao H, Qi H, Ratnam M. Modulation of the folate receptor type beta gene by coordinate actions of retinoic acid receptors at activator Sp1/ets and repressor AP-1 sites. Blood 2003; 101:4551–4560.[Abstract/Free Full Text] Bush TS, St Coeur M, Resendes KK, Rosmarin AG. GA-binding protein (GABP) and Sp1 are required, along with retinoid receptors, to mediate retinoic acid responsiveness of CD18 (beta 2 leukocyte integrin): a novel mechanism of transcriptional regulation in myeloid cells. Blood 2003; 101:311–317.[Abstract/Free Full Text] Grignani F, Gelmetti V, Fanelli M, et al. Formation of PML/RAR alpha high molecular weight nuclear complexes through the PML coiled-coil region is essential for the PML/RAR alpha-mediated retinoic acid response. Oncogene 1999; 18:6313–6321.[CrossRef][Medline] [Order article via Infotrieve] Ruthardt M, Testa U, Nervi C, et al. Opposite effects of the acute promyelocytic leukemia PML-retinoic acid receptor alpha (RAR alpha) and PLZF-RAR alpha fusion proteins on retinoic acid signalling. Mol Cell Biol 1997; 17:4859–4869.[Abstract] Jansen JH, de Ridder MC, Geertsma WM, et al. Complete remission of t(11;17) positive acute promyelocytic leukemia induced by all-trans retinoic acid and granulocyte colony-stimulating factor. Blood 1999; 94:39–45.[Abstract/Free Full Text] Sternsdorf T, Phan VT, Maunakea ML, et al. Forced retinoic acid receptor alpha homodimers prime mice for APL-like leukemia. Cancer Cell 2006; 9:81–94.[CrossRef][Medline] [Order article via Infotrieve] Zhu J, Nasr R, Peres L, et al. RXR is an essential component of the oncogenic PML/RARA complex in vivo. Cancer Cell 2007; 12:23–35.[CrossRef][Medline] [Order article via Infotrieve] CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: R. Nasr, V. Lallemand-Breitenbach, J. Zhu, M.-C. Guillemin, and H. de The Therapy-induced PML/RARA Proteolysis and Acute Promyelocytic Leukemia Cure Clin. Cancer Res., October 15, 2009; 15(20): 6321 - 6326. [Abstract] [Full Text] [PDF] J. B. Wu, K. Chen, X.-M. Ou, and J. C. Shih Retinoic Acid Activates Monoamine Oxidase B Promoter in Human Neuronal Cells J. Biol. Chem., June 19, 2009; 284(25): 16723 - 16735. [Abstract] [Full Text] [PDF] A. Saumet, G. Vetter, M. Bouttier, E. Portales-Casamar, W. W. Wasserman, T. Maurin, B. Mari, P. Barbry, L. Vallar, E. Friederich, et al. Transcriptional repression of microRNA genes by PML-RARA increases expression of key cancer proteins in acute promyelocytic leukemia Blood, January 8, 2009; 113(2): 412 - 421. [Abstract] [Full Text] [PDF] S. van Wageningen, G. Nikoloski, G. Vierwinden, R. Knops, B. A. van der Reijden, and J. H. Jansen The transcription factor nuclear factor Y regulates the proliferation of myeloid progenitor cells Haematologica, October 1, 2008; 93(10): 1580 - 1582. [Full Text] [PDF] This Article Abstract Full Text (PDF) Supplemental Figures All Versions of this Article: blood-2007-04-081125v1 111/3/1634    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by van Wageningen, S. Articles by Jansen, J. H. Search for Related Content PubMed PubMed Citation Articles by van Wageningen, S. Articles by Jansen, J. H. Related Collections Neoplasia Social Bookmarking                   What's this?

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020